Several studies have analyzed the role of allogeneic BMT (alloBMT) in adult patients with acute lymphoblastic leukemia (ALL) in first CR in comparison with chemotherapy and/or autologous transplant.
1-4 However, there are lack of information on long-term follow-up and complications in these patients. The patients treated with alloBMT or chemotherapy alone may have a different spectrum of long-term complications.
We reported earlier on the results of 92 adult patients below the age of 55 years with ALL treated at Princess Margaret Hospital from September 1992 to October 2001. 2 According to the institutional policy, these patients were offered alloBMT in first CR if a related donor was available. Unrelated donor transplants were offered to Ph positive ALL (Ph þ ALL) patients. Of the 87 patients achieving first CR with induction therapy, the comparison of patients with (n ¼ 48) or without donors (n ¼ 39) did not show any significant difference in leukemia-free survival or OS.
Long-term survivors of chemotherapy and alloBMT are followed up regularly in our program. This gave us an opportunity to study long-term issues in this cohort. The present report is a mature follow-up of our previous study with a median follow-up of 105 months (interquartile range 84-133) with additional information on long-term complications. The study was approved by the Research and Ethics Board of University Health Network.
There were 39 long-term survivors with recent follow-up data available for 35 (90%). We did a detailed chart review of the surviving patients. In addition to disease control and survival, we collected detailed information on medication history, Karnofsky performance scores at last follow-up, clinic visits in the year preceding the last follow-up date, employment/return to school status, secondary malignancies, fertility status and complications related to various organ systems.
The cumulative probability of relapse, leukemia-free survival and OS at 10 year was 47% (95% confidence interval 38-59), 40% (95% confidence interval 30-50) and 45% (95% confidence interval 34-55), respectively. No significant difference was observed in the 'donor' group and 'no donor' group for relapse (57% (43-75) vs 40% (28-56), P ¼ 0.12), leukemia-free survival (38 vs 43%, P ¼ 0.60) or OS (42 vs 48%, P ¼ 0.47, Figure 1 ) at 10 years.
The long-term complications in the 'donor' (n ¼ 20) and 'no donor' (n ¼ 19) group are summarized in Table 1 . All but one patient had good performance scores. This patient was still on immunosuppressive therapy for GVHD. The spectrum of long-term complications was different in the two groups. Most frequent complications in the 'donor' group were related to eyes, bones, lungs and hyperlipidemia. In comparison, the patients in the 'no donor' group had primarily bone-related complications followed by hypothyroidism. None of the survivors developed a secondary malignancy.
Eye complications were the most frequent complications reported in the patients who received alloBMT. All patients undergoing alloBMT received conditioning regimen of cyclophosphamide and TBI. As expected, the incidence of cataract was significantly high in the 'donor' group. Cataract is a well-known complication in transplant recipients undergoing TBI-based conditioning regimen. 5, 6 Of the 10 patients in 'donor' group with eye complications, 7 developed cataract and the other 3 had 'dry eyes' from GVHD. In the 'no donor' group, one patient had third nerve palsy because of zoster infection and the other one had cataract. The higher number of patients with cataracts in the 'donor' group was the only statistically significant difference between the two groups (P ¼ 0.01).
Chemotherapy protocols for ALL rely heavily on steroids increasing the risk of bone-related complications. This seems to be a significant problem in long-term survivors. 7 The incidence of osteonecrosis appears high in both groups. Six patients had osteonecrosis of hip or knee joint and others were diagnosed with osteoporosis on bone www.nature.com/bmt mineral density scans. Of the six patients with osteonecrosis, four were only treated with chemotherapy. Therefore, it is important to be vigilant regarding bone-related complications in these patients and include bone loss prevention strategies in the treatment protocols.
Previous studies in long-term survivors of allogeneic transplants have shown a higher risk of cardiovascular and metabolic complications. 8, 9 In our study, diabetes, hypothyroidism and hyperlipidemia were observed in 4 (11%), 9 (26%) and 10 (30%) patients, respectively. One patient had myocardial infarction. Hypertension requiring regular treatment was observed in seven patients (17.9%).
Pulmonary complications or abnormal pulmonary function tests (defined as 20% or more decline of baseline FEV1 or diffusion capacity) were observed in 10 patients (three in the 'no donor' group and seven in the 'donor' group). Of these 10 patients, 7 patients were asymptomatic and pulmonary complications were detected on regular annual pulmonary function tests. Three patients had significant symptoms from pulmonary disease: one in the 'donor' group had significant pulmonary compromise because of lung GVHD and two patients in the 'no donor' group were diagnosed with 'MTX' lung.
Fertility information was collected for 35 of the 39 survivors who were under the age of 45 at the time of diagnosis. Of these, eight reported pregnancy (n ¼ 5) or fathered (n ¼ 3) a child after treatment. Of the five female patients reporting pregnancies, four were treated with chemotherapy alone and one received alloBMT. Of the three male patients who fathered a child, there were two allotransplant recipients and one patient treated with chemotherapy alone.
It is important to note that despite these long-term complications, a large proportion of survivors have been able to return to study/employment and become a productive part of society irrespective of the treatment strategy. Information regarding employment/return to school was available on 37 (95%) patients. Of these, 34 (92%) returned to employment/school on full-or part-time basis at the last follow-up. There were no significant differences in the two groups in terms of performance status or return to employment/school.
Our study shows that the survivors of ALL treated with either chemotherapy or alloBMT have significant long-term health issues indicating the need for long-term follow-up and systematic research in this area. As the pool of adult acute leukemia survivors increases, it is important to invest adequate research efforts in this area so as to develop appropriate strategies.
